Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
7 Stocks to Buy That Can Soar in Good Times or in Bad
04:55pm, Thursday, 22'nd Sep 2022
Many commentators, analysts, and economists are convinced that the U.S. will enter a recession next year. Given the strength of the labor market and of corporate balance sheets, along with the onshori
AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in Europe
03:30pm, Thursday, 22'nd Sep 2022 Zacks Investment Research
AstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.
Reuters
CATL's 3rd Largest Customer After Tesla, Nio Cuts Reliance On Battery Giant In Bid For Diversification
XPeng Inc (NYSE: XPEV) has diversified its battery suppliers and does not count indu
Spero's stock jumps 188% after GSK licenses experimental antibiotic
10:53am, Thursday, 22'nd Sep 2022
Shares of Spero Therapeutics Inc. SPRO, +277.39% soared 188.4% in trading on Thursday morning after the company signed an exclusive license agreement with GlaxoSmithKline GSK, -0.32% for its experimen
GSK to shell out an initial US$75mln to gain rights to a next-generation antibiotic
02:57am, Thursday, 22'nd Sep 2022
GSK PLC (LSE:GSK, NYSE:GSK) has inked a licensing deal with a Cambridge, Massachusetts, biotech that will give it access to an oral antibiotic for complicated urinary tract infections. The UK group is
Merck (MRK) Resumes HIV Studies on Islatravir With Lower Dose
04:16pm, Wednesday, 21'st Sep 2022 Zacks Investment Research
Merck's (MRK) new phase III studies are set to evaluate a once-daily oral combination of doravirine and a lower dose of islatravir
Is Trending Stock GSK PLC Sponsored ADR (GSK) a Buy Now?
01:00pm, Wednesday, 21'st Sep 2022 Zacks Investment Research
Glaxo (GSK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Trending Stock GSK PLC Sponsored ADR (GSK) a Buy Now?
10:32am, Wednesday, 21'st Sep 2022
Glaxo (GSK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
2 Dividend Stocks to Double Up On Right Now
02:45pm, Tuesday, 20'th Sep 2022 The Motley Fool
These pharma giants are ideal for long-term investors because of their consistent growth and above-average dividend yields.
Company News for Sep 20, 2022
01:36pm, Tuesday, 20'th Sep 2022 Zacks Investment Research
Companies in The News Are: WIX,COIN,TBPH,GSK,MRNA
2 Dividend Stocks to Double Up On Right Now
10:45am, Tuesday, 20'th Sep 2022
These pharma giants are ideal for long-term investors because of their consistent growth and above-average dividend yields.
Haleon impresses with results and rejection of indemnity requests from GSK and Pfizer
08:19am, Tuesday, 20'th Sep 2022
Haleon PLC (LSE:HLN, NYSE:HLN) shares recouped some of their losses since being spun out of GSK earlier this year as the consumer healthcare group rejected any liability in the Zantac lawsuits that ha
Haleon rejects Zantac indemnification requests from GSK, Pfizer
02:17am, Tuesday, 20'th Sep 2022
Haleon on Tuesday said it had notified GSK and Pfizer that it had rejected their requests for indemnification in relation to U.S.-based litigation over the heartburn drug, Zantac.
WHO Recommends Gilead's (GILD) Veklury for Severe COVID-19
06:58pm, Friday, 16'th Sep 2022 Zacks Investment Research
Gilead's (GILD) Veklury is now recommended by the WHO for use in both non-severe COVID-19 patients at the highest risk of hospitalization and those with severe COVID-19.
Pfizer's (PFE) Late-Stage Meningococcal Jab Study Meets Goal
05:41pm, Friday, 16'th Sep 2022 Zacks Investment Research
Based on positive top-line data from phase III on its pentavalent meningococcal vaccine, Pfizer (PFE) intends to submit a regulatory application to the FDA seeking approval by year-end.
